ABSORPTION CHARACTERISTICS OF CHEMICALLY MODIFIED-INSULIN DERIVATIVES WITH VARIOUS FATTY-ACIDS IN THE SMALL AND LARGE-INTESTINE

被引:146
作者
ASADA, H [1 ]
DOUEN, T [1 ]
WAKI, M [1 ]
ADACHI, S [1 ]
FUJITA, T [1 ]
YAMAMATO, A [1 ]
MURANISHI, S [1 ]
机构
[1] KYOTO PHARMACEUT UNIV, DEPT BIOPHARMACEUT, YAMASHINA KU, KYOTO 607, JAPAN
关键词
D O I
10.1002/jps.2600840604
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Absorption characteristics of insulin derivatives chemically modified with various fatty acids in the intestine were determined by in situ loop and in vitro modified Ussing chamber methods. The pharmacological activities of these acyl derivatives, as assessed by their hypoglycemic effects after intravenous administration, were reduced upon increasing the carbon number of the fatty acid(s) chemically attached to native insulin. However, high pharmacological activities were seen when mono- and dicaproyl derivatives were administered intravenously. The absorption of insulin after its small intestinal administration could be hardly improved by acylation. In contrast, its absorption after the large intestinal administration was increased by increasing the number of caproic acid molecules attached to insulin. Furthermore, by an in vitro modified Ussing chamber method, it was revealed that the permeability of insulin across both the duodenal and colonic mucous membranes was also improved by increasing the number of caproic acid molecules. These in situ and in vitro results indicated that the chemical modification of insulin with fatty acids was a useful approach for improving insulin absorption from the large intestine.
引用
收藏
页码:682 / 687
页数:6
相关论文
共 30 条
  • [1] Hirai S., Yashiki T., Mima H., Int. J. Pharm., 9, pp. 165-172, (1981)
  • [2] Hirai S., Yashiki T., Mima H., Int. J. Pharm., 9, pp. 173-184, (1981)
  • [3] Gordon G.S., Moses A.C., Silver R.D., Flier J.S., Carey M.C., Proc. Natl. Acad. Sci. USA., 82, pp. 7419-7423, (1985)
  • [4] Tengamnuay P., Mitra A.K., Pharm. Res., 7, pp. 370-375, (1990)
  • [5] Uchida N., Maitani Y., Machida Y., Nakagaki M., Nagai T., Ind. Pharm., 17, pp. 1625-1634, (1991)
  • [6] Liu F.Y., Shao Z., Kildsig D.O., Mitra A.K., Pharm. Res., 10, pp. 228-232, (1993)
  • [7] Yamamoto A., Umemori S., Muranishi S., J. Pharm. Pharmacol., 46, pp. 14-18, (1994)
  • [8] Yamamoto A., Luo A.M., Dodda-Kashi S., Lee V.H.L., J. Pharmacol. Exp. Ther., 249, pp. 249-255, (1989)
  • [9] Nishihata T., Okumura Y., Inagaki H., Sudoh M., Kamada A., Yagi T., Kawamori R., Shichiri M., Int. J. Pharm., 34, pp. 157-161, (1986)
  • [10] Yamamoto A., Hayakawa E., Kato Y., Nishihata A., Lee V.H.L., J. Pharmacol. Exp. Ther., 263, pp. 25-31, (1992)